Clinical trial
A Phase 2 Study of Teclistamab in Combination With Daratumumab or Lenalidomide in Elderly Patients With Newly Diagnosed Multiple Myeloma
NCT05572229 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Teclistamab in Combination With Daratumumab or Lenalidomide in Elderly Patients With Newly Diagnosed Multiple Myeloma
- Lead sponsor
- University Hospital, Lille
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 21, 2023
- Completion date
- September 30, 2032
- Enrollment
- 74 (estimated)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.